Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Core Insights - Aardvark Therapeutics is advancing ARD-201, a novel therapy aimed at improving glucose control and preserving lean mass, addressing challenges in obesity treatment [1][3] - The company plans to initiate two Phase 2 trials for ARD-201, named POWER and STRENGTH, to evaluate its efficacy in preventing weight regain and promoting weight loss [2][13] ARD-201 Obesity Program - ARD-201 is a fixed-dose combination of TAS2R agonist ARD-101 and DPP-4 inhibitor sitagliptin, designed to enhance appetite suppression and metabolic effects [3][10] - Preclinical studies indicate that ARD-201 can reduce fat mass while preserving lean mass, achieving glucose control comparable to high-dose tirzepatide [5][10] - Previous preclinical data showed ARD-201 resulted in approximately 19% weight loss after 30 days, similar to high-dose tirzepatide, and around 30% weight loss when combined with low-dose tirzepatide [5][10] Clinical Development - ARD-201 is set to enter the Phase 2 POWER trial by the end of 2025, focusing on preventing weight regain in subjects who have previously lost significant weight [13] - The STRENGTH trial is planned for the first half of 2026, assessing the potential for placebo-adjusted weight loss and the additive effects of ARD-201 with GLP-1RA therapy [13] Investor Engagement - Aardvark will host an investor webinar on November 5, 2025, to discuss the data presented at ObesityWeek and provide insights into ARD-101, ARD-201, and WE-868 [6][7]